Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of ALXN1210 vs Eculizumab in Adult PNH Patients Already Treated With Eculizumab
2016-002026-36Phase 3Unknown
- Sponsor
- Alexion Pharmaceuticals
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ravulizumab in paroxysmal nocturnal hemoglobinuria (PNH) (2 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: Hemolysis as directly measured by lactate dehydrogenase percent change (LDH-PCHG). Status: unknown.
02
Drugs
ravulizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2016-002026-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002026-36.